Latest Gastrointestinal cancer Stories

If link proves causal, 1 in 12 of these cancers might be prevented, say researchers Increasing dietary intake of the antioxidant vitamins C, E, and selenium could help cut the risk of developing pancreatic cancer by up to two thirds, suggests research published online in the journal Gut. If the association turns out to be causal, one in 12 of these cancers might be prevented, suggest the researchers, who are leading the Norfolk arm of the European Prospective Investigation of Cancer...

-Liver cancer is the third leading cancer killer worldwide and new treatments are urgently needed. -This study shows that loss of a regulatory molecule called microRNA-122 leads to liver cancer. -The findings suggest that developing a drug that restores microRNA-122 levels might offer a new way to treat this deadly disease. A new study shows that loss of a small RNA molecule in liver cells might cause liver cancer and that restoring the molecule might slow tumor growth and offer a new...

MANHATTAN BEACH, Calif., July 23, 2012 /PRNewswire/ -- The Pancreatic Cancer Action Network today released the following statement regarding the passing of Sally Ride, the first American woman to travel into space: (Logo: http://photos.prnewswire.com/prnh/20111004/LA79914LOGO) "Sally Ride was an inspiration for all Americans, not just young women who learned from her extraordinary example that anything is possible," said Julie Fleshman, president and CEO of the Pancreatic...

WAYNE, N.J., SOUTH SAN FRANCISCO, Calif. and TOKYO, July 23, 2012 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), and Astellas Pharma Inc. (TSE: 4503) today announced that a Phase 3 trial evaluating the efficacy and safety of the addition of Tarceva(®) (erlotinib) tablets to Nexavar(®) (sorafenib) tablets did not improve overall survival for patients with unresectable hepatocellular carcinoma (HCC) vs. Nexavar alone. The SEARCH (Sorafenib...

The Cancer Genome Atlas generates genomic data for colon and rectal cancers that point to potential targets for treatment The pattern of genomic alterations in colon and rectal tissues is the same regardless of anatomic location or origin within the colon or the rectum, leading researchers to conclude that these two cancer types can be grouped as one, according to The Cancer Genome Atlas (TCGA) project's large-scale study of colon and rectal cancer tissue specimens. In multiple types of...

PHOENIX, July 17, 2012 /PRNewswire/ -- The National Cancer Institute has awarded a $3 million grant to the College of Nursing and Health Innovation at Arizona State University to fund research to promote colorectal cancer (CRC) screening among underserved populations. Of cancers that affect both women and men, colorectal cancer is the second leading cancer killer in the US, according to the most current data from the Centers for Disease Control and Prevention. The four-year...

PARSIPPANY, N.J., July 17, 2012 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) granted Ferring Pharmaceuticals Inc. approval to market PREPOPIK (sodium picosulfate, magnesium oxide, and anhydrous citric acid) for oral solution indicated for cleansing of the colon as a preparation for colonoscopy in adults. PREPOPIK is a low-volume, orange-flavored, dual-acting, stimulant and osmotic laxative. The FDA approval is based on data from two pivotal Phase III non-inferiority...

NEW YORK, July 17, 2012 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) announced today that it will host a conference call and webcast on Tuesday, August 7, 2012 at 8:30 a.m. ET to discuss its financial results for the second quarter ended June 30, 2012, and provide an update on recent corporate progress. The dial-in number for the conference call is 800-762-8779 for domestic participants and 480-629-9645 for international participants. To access the live webcast, go to the...

A new study has determined how often people should get screened for gastric or stomach cancer in high-risk regions of the world. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings could help reduce deaths from gastric cancer, which is the second most common cause of cancer-related mortality. Although the incidence of gastric cancer has decreased substantially in the western part of the world, the disease is still common in areas such as...

STONY BROOK, N.Y., July 16, 2012 /PRNewswire/ -- Viatronix Incorporated announced today that the stage finally appears set for a reversal of the May 2009 non-coverage decision for screening CTC by The Centers for Medicare & Medicaid Services (CMS). The latest CTC study, "CT Colonography of a Medicare-Aged Population: Outcomes Observed in an Analysis of More Than 1400 Patients" (American Journal of Roentgenology, AJR2012; 199:W27-W34), provides overwhelming evidence that CT...